H Bläker1, A Warth, M Kloor, P Schirmacher. 1. Pathologisches Institut, Universitätsklinik Heidelberg, Heidelberg, Deutschland. hendrikblaeker@yahoo.de
Abstract
AIMS: Intestinal carcinogenesis is associated with genetic instability affecting either the chromosomal level (CIN) or microsatellite DNA sequences (MIN). In addition, epigenetic alterations, such as aberrant CpG island methylation (CIMP) may contribute to tumor development. While these single genetic alterations have frequently been addressed in intestinal carcinogenesis little is known about the interaction of the epigenetics and genetics in tumorigenesis. This investigation therefore aimed to define the synergistic effects of CIN, MSI and CIMP in small bowel adenocarcinomas. METHODS: A total of 37 primary small bowel adenocarcinomas were investigated for CIN, MSI, CIMP, KRAS and BRAF mutations. The results showed that CIN was found in 22 out of 37 (57%) tumors (3 out of 9 microsatellite instable and 19 out of 28 microsatellite stable carcinomas) and 9 carcinomas (24%) were microsatellite and chromosomally stable. Aberrant CIMP was detected in 16% of chromosomal instable tumors and in 44% of both microsatellite instable and microsatellite and chromosomally stable carcinomas, KRAS was mutated in 55%, 0% and 10% of chromosomal instable, microsatellite instable and microsatellite and chromosomal stable tumors, respectively, while BRAF mutations occurred in 6% of chromosomal instable and 22% of both microsatellite instable and microsatellite and chromosomal stable carcinomas. CONCLUSION: Chromosomal instable carcinomas of the small intestine are distinguished from microsatellite instable and microsatellite and chromosomal stable tumors by a high frequency of KRAS mutations and low frequencies of CIMP and BRAF mutations. In microsatellite instable and microsatellite and chromosomally stable cancers, CIMP and BRAF/KRAS mutations are similarly distributed indicating common mechanisms of tumor initiation or progression in the molecular pathogenesis.
AIMS: Intestinal carcinogenesis is associated with genetic instability affecting either the chromosomal level (CIN) or microsatellite DNA sequences (MIN). In addition, epigenetic alterations, such as aberrant CpG island methylation (CIMP) may contribute to tumor development. While these single genetic alterations have frequently been addressed in intestinal carcinogenesis little is known about the interaction of the epigenetics and genetics in tumorigenesis. This investigation therefore aimed to define the synergistic effects of CIN, MSI and CIMP in small bowel adenocarcinomas. METHODS: A total of 37 primary small bowel adenocarcinomas were investigated for CIN, MSI, CIMP, KRAS and BRAF mutations. The results showed that CIN was found in 22 out of 37 (57%) tumors (3 out of 9 microsatellite instable and 19 out of 28 microsatellite stable carcinomas) and 9 carcinomas (24%) were microsatellite and chromosomally stable. Aberrant CIMP was detected in 16% of chromosomal instable tumors and in 44% of both microsatellite instable and microsatellite and chromosomally stable carcinomas, KRAS was mutated in 55%, 0% and 10% of chromosomal instable, microsatellite instable and microsatellite and chromosomal stable tumors, respectively, while BRAF mutations occurred in 6% of chromosomal instable and 22% of both microsatellite instable and microsatellite and chromosomal stable carcinomas. CONCLUSION: Chromosomal instable carcinomas of the small intestine are distinguished from microsatellite instable and microsatellite and chromosomal stable tumors by a high frequency of KRAS mutations and low frequencies of CIMP and BRAF mutations. In microsatellite instable and microsatellite and chromosomally stable cancers, CIMP and BRAF/KRAS mutations are similarly distributed indicating common mechanisms of tumor initiation or progression in the molecular pathogenesis.
Authors: T L Chan; L C Curtis; S Y Leung; S M Farrington; J W Ho; A S Chan; P W Lam; C W Tse; M G Dunlop; A H Wyllie; S T Yuen Journal: Oncogene Date: 2001-08-09 Impact factor: 9.867
Authors: Karolin Trautmann; Jonathan P Terdiman; Amy J French; Ritu Roydasgupta; Nancy Sein; Sanjay Kakar; Jane Fridlyand; Antoine M Snijders; Donna G Albertson; Stephen N Thibodeau; Frederic M Waldman Journal: Clin Cancer Res Date: 2006-11-01 Impact factor: 12.531
Authors: Ajay Goel; Takeshi Nagasaka; Christian N Arnold; Toru Inoue; Cody Hamilton; Donna Niedzwiecki; Carolyn Compton; Robert J Mayer; Richard Goldberg; Monica M Bertagnolli; C Richard Boland Journal: Gastroenterology Date: 2006-09-20 Impact factor: 22.682
Authors: Yu-Wei Cheng; Hanna Pincas; Manny D Bacolod; Gunter Schemmann; Sarah F Giardina; Jianmin Huang; Sandra Barral; Kamran Idrees; Sajid A Khan; Zhaoshi Zeng; Shoshana Rosenberg; Daniel A Notterman; Jurg Ott; Philip Paty; Francis Barany Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Wolfgang M Brueckl; Elvira Heinze; Catrin Milsmann; Axel Wein; Corinna Koebnick; Andreas Jung; Roland S Croner; Thomas Brabletz; Klaus Günther; Thomas Kirchner; Eckhart G Hahn; Werner Hohenberger; Heinz Becker; Bertram Reingruber Journal: Cancer Lett Date: 2004-01-20 Impact factor: 8.679
Authors: Long Shan Li; Nam-Gyun Kim; Se Hoon Kim; Chanil Park; Hyunki Kim; Hyun Ju Kang; Kwi Hye Koh; Soo Nyung Kim; Won Ho Kim; Nam Kyu Kim; Hoguen Kim Journal: Am J Pathol Date: 2003-10 Impact factor: 4.307
Authors: Wojciech Kwasniewski; Anna Gozdzicka-Jozefiak; Maria Wolun-Cholewa; Grzegorz Polak; Jadwiga Sierocinska-Sawa; Anna Kwasniewska; Jan Kotarski Journal: Mol Med Rep Date: 2016-04-25 Impact factor: 2.952